We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Emerging role of antidiabetic drugs in cardiorenal protection.
- Authors
Wen-Jia Fu; Jin-Ling Huo; Zi-Hui Mao; Shao-Kang Pan; Dong-Wei Liu; Zhang-Suo Liu; Peng Wu; Zhong-Xiuzi Gao
- Abstract
The global prevalence of diabetes mellitus (DM) has led to widespread multisystem damage, especially in cardiovascular and renal functions, heightening morbidity and mortality. Emerging antidiabetic drugs sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase-4 inhibitors (DPP-4i) have demonstrated efficacy in preserving cardiac and renal function, both in type 2 diabetic and nondiabetic individuals. To understand the exact impact of these drugs on cardiorenal protection and underlying mechanisms, we conducted a comprehensive review of recent large-scale clinical trials and basic research focusing on SGLT2i, GLP-1RAs, and DPP-4i. Accumulating evidence highlights the diverse mechanisms including glucose-dependent and independent pathways, and revealing their potential cardiorenal protection in diabetic and non-diabetic cardiorenal disease. This review provides critical insights into the cardiorenal protective effects of SGLT2i, GLP-1RAs, and DPP-4i and underscores the importance of these medications in mitigating the progression of cardiovascular and renal complications, and their broader clinical implications beyond glycemic management.
- Subjects
SODIUM-glucose cotransporters; CANAGLIFLOZIN; EXENATIDE; GLUCAGON-like peptide-1 receptor; SODIUM-glucose cotransporter 2 inhibitors; HYPOGLYCEMIC agents; GLUCAGON-like peptide-1 agonists; CD26 antigen
- Publication
Frontiers in Pharmacology, 2024, p1
- ISSN
1663-9812
- Publication type
Article
- DOI
10.3389/fphar.2024.1349069